Clinical Trial Update: Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of Cirtuvivint and Olaparib for BRCA/Homologous Recombination Deficiency–related platinum-resistant ovarian cancer, inc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrioid Ovarian Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Cirtuvivint
• Lynparza (olaparib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Endometrioid Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 | Status: RECRUITING